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http://www.trialsjournal.com/content/15/1/391STUDY PROTOCOL Open AccessEffects of varenicline and cognitive bias
modification on neural response to smoking-
related cues: study protocol for a randomized
controlled study
Angela S Attwood1,2,3*, Tim Williams4, Sally Adams2,4, Francis J McClernon5 and Marcus R Munafò1,2,3Abstract
Background: Smoking-related cues can trigger drug-seeking behaviors, and computer-based interventions that
reduce cognitive biases towards such cues may be efficacious and cost-effective cessation aids. In order to optimize
such interventions, there needs to be better understanding of the mechanisms underlying the effects of cognitive bias
modification (CBM). Here we present a protocol for an investigation of the neural effects of CBM and varenicline in
non-quitting daily smokers.
Methods/Design: We will recruit 72 daily smokers who report smoking at least 10 manufactured cigarettes or 15 roll-ups
per day and who smoke within one hour of waking. Participants will attend two sessions approximately one week apart.
At the first session participants will be screened for eligibility and randomized to receive either varenicline or a placebo
over a seven-day period. On the final drug-taking day (day seven) participants will attend a second session and
be further randomized to one of three CBM conditions (training towards smoking cues, training away from
smoking cues, or control training). Participants will then undergo a functional magnetic resonance imaging
scan during which they will view smoking-related pictorial cues. Primary outcome measures are changes in
cognitive bias as measured by the visual dot-probe task, and neural responses to smoking-related cues. Secondary
outcome measures will be cognitive bias as measured by a transfer task (modified Stroop test of smoking-related
cognitive bias) and subjective mood and cigarette craving.
Discussion: This study will add to the relatively small literature examining the effects of CBM in addictions. It will
address novel questions regarding the neural effects of CBM. It will also investigate whether varenicline treatment
alters neural response to smoking-related cues. These findings will inform future research that can develop behavioral
treatments that target relapse prevention.
Trial registration: Registered with Current Controlled Trials: ISRCTN65690030. Registered on 30 January 2014.Background
Smoking remains a significant public health concern,
with tobacco-related deaths being estimated at around 6
million per year [1]. Despite many smokers reporting
wanting to quit, few achieve long-term abstinence. Many
episodes of drug relapse, including relapse to smoking,* Correspondence: angela.attwood@bristol.ac.uk
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2UK Centre for Tobacco and Alcohol Studies, University of Bristol, 12a Priory
Road, Bristol BS8 1TU, UK
Full list of author information is available at the end of the article
© 2014 Attwood et al.; licensee BioMed Centr
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.occur in the presence of drug-related cues [2,3]. Through
repeated and contingent pairing with drug administration,
these cues acquire powerful motivational properties
that can precipitate craving and drug-seeking [4-7].
Drug-related cognitive biases, characterized by select-
ive or disproportionate attention allocation to drug
cues, have been reported in users of a number of drugs
and have been positively associated with drug craving
[8,9], future drug use [10], approach behaviors to
drug-related cues [11], and increased likelihood of re-
lapse [12]. Of particular importance, the drug-stimulus
learning that is believed to underlie these biases isal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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relapse long after initial cessation. In smokers, in-
creased reactivity to smoking cues has been found to
predict decreased likelihood of cessation [13,14]. Con-
sequently, reduction in cognitive bias is considered a
promising target for therapeutic intervention.
Recent research indicates that it is possible to reduce
cognitive biases using computer-based cognitive bias
modification (CBM) paradigms that train individuals to
allocate attention away from disorder-relevant cues.
CBM has been shown to reduce cognitive biases in
anxiety and depression [15-17] and has also been associ-
ated with reduction in other symptoms [18]. Attwood
et al. [19] investigated the effect of a single session of
stimulus-avoidant CBM using a modified dot-probe task,
and reported decreases in cognitive bias in daily
smokers. Compared to a group who had been trained to
attend to smoking cues, there was evidence that the
avoid group also showed attenuated craving in response
to in vivo smoking cues in a subsequent cue exposure
test (male participants only). The current study will ex-
tend earlier work by investigating the neural responses
to smoking-related cues following CBM. The neuroim-
aging literature suggests that drug-related cognitive
biases are the results of a failure of cognitive regulatory
systems to increase control in the presence of salient
cues that increase processing in the reward and emo-
tional centers of the brain (such as the striatum and
amygdala) [20]. These data will enable the investigation
of whether CBM decreases emotional responses to drug-
related cues or increases cognitive control in their pres-
ence, and will thereby increase understanding of the
mechanisms that underlie CBM effects.
There has been a recent suggestion that the smoking
cessation pharmacotherapy varenicline reduces cue-
induced craving and cue-induced reinstatement of drug-
taking in animals [21-24]. This study will include a
pharmacological challenge that randomizes participants to
receive seven days treatment of either varenicline or pla-
cebo prior to a functional Magnetics Resonance Imaging
(fMRI) scan, in order to assess neural cue-reactivity fol-
lowing varenicline treatment. Previous research has re-
ported differences in neural response to smoking cues
following varenicline treatment [25], but the sample sizes
were small and the effects require replication.
Study objectives and hypotheses
The primary objective is to investigate the neural effects
of CBM in response to smoking-related cues in current
daily smokers. A secondary objective is to examine the
effects of varenicline treatment on neural responses to
smoking cues. We will also explore whether there is any
pattern in the data to suggest that the effects of CBM
are modified by concurrent treatment with varenicline.The CBM methods we will use are delivered via computer,
and can therefore in principle be delivered remotely and
repeatedly at low cost, for example via the internet or
smartphones, as an adjunctive treatment to varenicline
pharmacotherapy. To investigate whether CBM and vare-
nicline effects generalize to other measures of cognitive
bias, participants will also complete a modified pictorial
Stroop task before and after CBM and varenicline.
We hypothesize that: 1) CBM designed to induce cog-
nitive bias towards smoking-relates cues will lead to an
increase in cognitive bias and neural response to
smoking-related cues in brain regions previously impli-
cated in cue reactivity in cigarette smokers; 2) CBM
designed to induce cognitive bias away from smoking-
relates cues will lead to a decrease in cognitive bias and
neural response to smoking-related cues in brain regions
previously implicated in cue reactivity in cigarette
smokers; and 3) varenicline treatment will lead to a re-
duction in the neural response to smoking-related cues.
Methods/Design
Trial design
This is a human laboratory study assessing behavioral
and neural outcomes of CBM. The study design is a
two × three between-subjects model with one factor of
drug (varenicline or placebo) and one factor of CBM
group (attend, avoid, or control). For the behavioral as-
sessments of cognitive bias (dot-probe and modified
Stroop) and cue reactivity (cue exposure task in scan-
ner), there will be an additional within-subjects factor of
cue type (smoking or neutral).
Participants and recruitment
Current smokers (n =72; 50% male) will be recruited
from the staff and students at the University of Bristol
(United Kingdom) and the general population. A
CONSORT diagram of participant recruitment is shown
in Figure 1. Participants will be recruited through existing
email lists and poster and flyer advertisements, and by
word of mouth. Participants who are interested in taking
part will be sent the study information sheets and a tele-
phone screening will be arranged to assess basic eligibility.
Those who meet the study inclusion criteria will be
booked in for two sessions approximately one week apart.
Participants will receive £70 compensation for their time
for participation. Full written informed consent will be
obtained from each participant at the start of the study
session. Participants will be given a copy of the informa-
tion and consent form to keep.
Study setting
All study sessions will be run at the Clinical Research
and Imaging Centre at the University of Bristol, United
Kingdom.
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Figure 1 CONSORT flow diagram. CBM, cognitive bias modification.
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For inclusion, participants should be aged between 18
and 40 years, smoke at least 10 manufactured or 15 roll-
up cigarettes per day, and smoke within one hour of
waking in the morning. They should report availability
to attend all of the study sessions and be able to adhere
to all study requirements (including adhering to the
seven-day drug administration regimen). Participants
should have English as a first language, or have an
equivalent level of fluency, and be able to give informed
consent.
Exclusion criteria
Participants will be excluded from this study if they
have current or past alcohol or drug misuse and/or de-
pendence, psychiatric illness, or clinically significant
abnormality (including cardiovascular risk factors).
Participants should not have ongoing use of any medi-
cation (at least eight weeks clear of any prescribed
medication). Female participants should not be preg-
nant, breastfeeding, or at risk of becoming pregnant(not using adequate contraception). All participants
must be registered with a GP, should not consume
more than eight caffeinated beverages per day or more
than 35 alcoholic units per week if female, or 50 alco-
holic units per week if male (1 unit = a half pint
(284 ml) of ordinary strength (3.5 to 4% alcohol-by-
volume (ABV)) beer, a small glass (125 ml) of 8% ABV
of wine, or a single measure (25 ml) of a 40% ABV
spirit). They should not be actively trying to give up
smoking and not be planning to quit during the study
period. They should not have an uncorrected visual
(including colour blindness) or auditory impairment or
any known hypersensitivity to varenicline. Finally, they
should not have any condition that would make mag-
netic resonance imaging (MRI) scanning unsafe or in-
tolerable (such as metallic implants).
Ethical considerations and informed consent
Ethics approval was obtained from the National Research
Ethics Service (London Brent Committee; REC reference:
11/LO/1726). The study will be conducted according to
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Clinical Practice guidelines. The investigator or co-
investigator will explain the nature, purpose, and risks
of the study to the participant. The participant will re-
ceive the information sheet in advance of the study ses-
sions. There will be no time restriction on how long
participants take to respond, with the exception that
participants who respond after all study places have
been filled will not be offered a place on the study.
Therefore, participants will be given sufficient time to
read the information and consider any implications,
and to raise any questions with the investigators prior
to making a decision to participate. Participants will be
informed that they are free to withdraw at any time.
Sample size determination
As our primary objective is to investigate the effects of
CBM training on neural response to smoking-related
cues, the sample size determination was based on this
outcome. However, the effects of cognitive bias on
neural responses to smoking cues have not been evalu-
ated in previous research. To estimate the required sam-
ple size we used data from our previous study [19] that
indicated a likely increase in the cognitive bias index of
30 ms in the attend group, and a decrease of 30 ms in
the avoid group. We assume that the change in the con-
trol condition will be intermediate (0 ms). We will there-
fore achieve greater than 80% power to detect a linear
effect across the three CBM groups on change in cogni-
tive bias index with a total sample size of n = 30, at an
alpha level of 0.05. Using data from a study that com-
pared craving in response to smoking cues in groups
who had received treatment of varenicline (mean = 11.2,
standard deviation = 4.7) versus placebo (mean = 14.6,
standard deviation = 4.7), we estimate a total sample size
of 64 is required to achieve 80% power at an alpha level
of 0.05. As we expect some attrition, we will use a more
conservative estimate of n = 72.
Randomization
Participants will be randomly assigned to drug and CBM
groups, but equal numbers of participants per group will
be maintained. The drugs will be prepared by University
Hospitals Bristol Pharmacy who will produce two batches
of 36 bottles (one for males and one for females) that
comprise 18 bottles of varenicline and 18 bottles of pla-
cebo. Each bottle will be given a numeric identifier that
enables study staff involved in data collection to be fully
blinded to drug condition.
In advance of the study, an experimental collaborator
(who will have no direct contact with the study partici-
pants) will prepare a numeric code using random number
assignment software to further randomize participants to
CBM groups. Randomization will be stratified so thatequal numbers of male and female participants will be al-
located to each experimental cell.
Drug administration
Following initial consent and screening on day zero, var-
enicline (or matched placebo) will be prescribed for one
week, to be taken as 0.5 mg once daily for days one to
three, as 0.5 mg twice daily for days four to six, and as
0.5 mg once daily for day seven, consistent with the
standard dosing regimen for smoking cessation. Partici-
pants will attend their second session on day seven (their
last drug intake day) and will be advised to take the drug
in the morning prior to their study session.
Study medication will be administered to the partici-
pant by a designated medical doctor following screening
on day zero. This method of prescription is comparable
with the administration of varenicline in general prac-
tice. Participants will be required to complete a daily
diary detailing the time at which drugs are taken and
any side effects. They will be asked to bring the diary
and drug bottle to their second session.
Outcome measures
Primary outcome measures are changes in cognitive bias
as measured by the visual dot-probe task, and neural re-
sponses to smoking-related cues. Secondary outcome
measures will be cognitive bias as measured by a transfer
task (modified Stroop test) and subjective mood and
cigarette craving as measured by the Questionnaire of
Smoking Urges (QSU) and the Minnesota Nicotine
Withdrawal Scale (MNWS). Measures and materials.
Materials
Stimuli for the CBM and fMRI cue exposure task com-
prise 32 full-colour smoking-related pictures and 32
neutral pictures. Smoking-related cues consist of full-
colour pictures of people smoking. Control cues consist
of full-colour pictures of people engaged in everyday ac-
tivities (such as talking on the telephone or writing).
Equal numbers of females and males are represented in
each category. The set of cues pictures is the same as
those used in previous imaging studies [26]. For the cog-
nitive bias modification task, an additional four picture
pairs, unrelated to smoking, are used in practice and
buffer trials.
Cognitive bias modification
For the CBM, participants will be randomized to complete
a version of the visual probe task designed to induce a
biased cognitive response away from (avoid: n = 24), or to-
wards (attend: n = 24) smoking-related cues, or a control
condition (control: n = 24) designed not to modify cogni-
tive bias. Each task version comprises a total of 768 trials.
On each trial, following a 500 ms duration fixation cross, a
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When this picture pair disappears, a probe is presented in
either of the two screen locations previously occupied by a
picture. This probe is either a small circle or square. Par-
ticipants are required to discriminate between the identity
of each probe by pressing the arrow keys on the keyboard
as appropriate, and the response latency is measured. The
majority (n = 512) of trials are training trials, presented in
four blocks, and the remainder (n = 256) of trials are test
trials. Half of the test trials (n = 128) are presented prior
to the training trials, and half (n = 128) after the training
trials, in order to assess the effect of the training trials on
cognitive bias. In the test trials, the probe appears with
equal frequency in the vicinity of both the smoking-
related or neutral pictures. In the training trials, the probe
appears in the vicinity of the neutral picture on 75% of tri-
als in the avoid condition, or appears in the vicinity of the
smoking-related picture on 75% of trials in the attend con-
dition, or appears with equal frequency in the vicinity of
neutral and smoking-related pictures in the control condi-
tion. The inter-trial interval is jittered between 750 ms
and 1,250 ms in order to reduce the monotony of the task.
The sequence of events will be controlled using EPrime
version 2 software (Psychology Software Tools Inc.,
Pittsburgh, Pennsylvania, United States), and the total
task time is approximately 50 minutes.
Cognitive bias test (modified Stroop)
A pictorial version of the modified Stroop task will be
used in favor of the more traditional lexical version, due
to recent evidence of greater internal reliability of pictor-
ial versions of the task [27]. The task begins with 16
practice trials followed by two experimental blocks, each
comprising eight buffer and 96 experimental trials (208
trials in total). For each trial a picture is presented
(smoking-related or neutral) centrally on screen. The
picture is surrounded by a colored border and the par-
ticipant is required to identify the colour of the border
(red, blue, yellow, or green) using colour-marked keys
on the keyboard (d, f, j, and k).
Questionnaires
The questionnaire measures will include the Eysenck
Personality Questionnaire - Revised (EPQ-R) [28], the
Questionnaire of Smoking Urges - Brief (QSU-Brief )
[29], the Minnesota Nicotine Withdrawal Scale (MNWS)Figure 2 Timeline of cue-exposure task conducted during the functio[30], and visual analogue scales (VAS) of mood and
cigarette craving. These data will be used to examine
group differences at baseline and to assess any changes
in mood or craving across the course of the study.functional Magnetic Resonance Imaging(fMRI) acquisition
An anatomical and an fMRI scan will be performed on
the test day session (day seven). During the fMRI cue ex-
posure procedure, smoking-related and control cues will
be presented in a boxcar design with four blocks per cat-
egory (Figure 2). Participants are required to make a
button press on each stimulus presentation to identify
they have seen the image (this does not terminate view-
ing time). Each block will be 40 seconds in length, dur-
ing which time eight cues will be presented. Before and
after each block, a crosshair will be presented for five
seconds. Participants will then be asked to rate their
craving level on an eight-point scale (‘none at all’ to ‘ex-
treme’). The scale will be presented for 10 seconds
followed by presentation of a crosshair for another
10 seconds. Thus, the total between-block interval is
25 seconds. The sequence of events will be controlled
using EPrime version 2 software (Psychology Software
Tools Inc., Pittsburgh, Pennsylvania, United States), and
the total task time is approximately 10 minutes. The
total MRI protocol will last approximately 15 minutes.Data collection procedures
Day zero will be for screening and baseline assessments.
After informed consent has been obtained, the screening
procedure will be conducted. Expired breath alcohol and
carbon monoxide readings will be taken and height,
weight, blood pressure, and heart rate measured. A urine
screen will be performed to test for recent drug use (all)
and pregnancy (females). A medical doctor will perform
a general physical and psychiatric health assessment
and prescribe the study medication if appropriate.
Post-screening, participants will complete a baseline
assessment of cognitive bias (modified Stroop) and
questionnaires assessing personality, cigarette craving,
and mood. They will also complete a practice version
of the task that will be used during the fMRI scan at
the second study visit.
Participants will be sent away with the study medica-
tion, medication packaging information, and a drug diarynal Magnetic Resonance Imaging.
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the next visit). The second session (test day) will be
scheduled for approximately one week later. This session
will fall on day seven of their drug regimen.
On the test day, participants will complete the modi-
fied Stroop task followed by a short visual dot-probe
task that measures baseline cognitive bias. They will
then be randomized to one of three conditions: 1) an ex-
perimental condition designed to induce cognitive bias
towards smoking-related cues (attend), 2) an experimen-
tal condition designed to induce cognitive bias away
from smoking-related cues (avoid), or 3) a control condi-
tion designed to induce no change in cognitive bias
(control). The test version of the dot-probe task will be
run again immediately post-CBM in order to assess
changes in cognitive bias.
Following this, participants will be taken to the scan-
ning suite. All participants will complete a four-minute
anatomical scan followed by the cue-exposure test dur-
ing a 15-minute fMRI scan. After scanning, participants
will complete the modified Stroop task and question-
naire state measures (QSU and visual analogue scales).
At the end of the test session, participants will be offered
smoking cessation literature, debriefed, and reimbursed
(£70).
Statistical plan
functional Magnetic Resonance Imaging analysis
Analyses will focus on evaluating neural activation dur-
ing viewing of smoking-related and control cues in the
three experimental groups. Pre-processing will be con-
ducted using statistical parametric mapping software
(Statistical Parametric Mapping 5; Wellcome Department
of Imaging Neuroscience, London, United Kingdom) to
remove noise and artefacts. The first four volumes of each
run will be discarded to allow for T1 stabilization. All
functional images will be corrected for acquisition timing
and head motion using rigid-body rotation and transla-
tion. Each participant’s data will then be warped into a
standard stereotaxic space (Montreal Neurological
Institute) with an isotropic 2 mm voxel size and
smoothed with an 8 mm full width at half measure
(FWHM) Gaussian filter.
Each participant’s fMRI data will then be entered into
a first-level voxel-by-voxel analysis using the general lin-
ear model. Each cue block (smoke or control) will be
modelled as a boxcar function convolved with a canon-
ical hemodynamic response function that begins at the
onset of the first cue in the block and ends at the end of
the block (60-second duration). A high-pass filter will be
applied to remove slow signal drift. A smoking-related
cue greater than control cue contrast image will then be
created and inputted into a random effects analysis. A
two (varenicline and placebo) × three (attend, avoid, andcontrol) mixed-model analysis of variance (ANOVA)will
be used to examine smoking cue reactivity (smoking
greater than control) between each group. Voxel-wise
analysis will be conducted within an Region of Interest
(ROI) mask. The mask will be created from anatomical
regions identified in a meta-analysis of cue reactivity
[31]: nucleus accumbens, caudate, putamen, temporal
gyrus, anterior cingulate gyrus, amygdala, insula, posterior
cingulate cortex, inferior frontal gyrus, and angular gyrus.
Each bilateral region will be selected using the WFU
PickAtlas tool [32] and combined to create the mask.
Resulting activations will be considered significant at an
alpha level of 0.001 (uncorrected) with a minimum cluster
extent threshold of 20 contiguous voxels. Post hoc analyses
of parameter estimates will be used to evaluate the nature
of significant effects. Smoking cue greater than control
cue contrast images for each participant will also be input
into random effect regression analyses examining relations
between post-training cognitive bias scores and neural cue
reactivity.Cognitive bias analyses
Cognitive bias scores will be calculated from reaction
time (RT) data from the visual probe task, by subtracting
RTs to probes that replace smoking-related pictures
from RTs to probes that replace neutral pictures, so that
positive scores represent a bias towards smoking cues
and negative scores represent a bias towards neutral
cues. These bias scores will be used to examine cognitive
training effects in a two (pre- and post-CBM) × two (var-
enicline and placebo) × three (attend, avoid, and control)
mixed-model ANOVA.
A two (smoking cue and neutral cue) × two (pre- and
post-CBM) × two (varenicline and placebo) × three (at-
tend, avoid, and control) mixed-model ANOVA will also
be conducted on the modified Stroop task RT and error
data. Participants will be excluded if their mean RT or
error score is three standard deviations (or more) below
or above the sample mean.Questionnaire analyses
To assess group differences at baseline two (varenicline
and placebo) × three (attend, avoid, and control) between-
subject ANOVAs will be conducted on EPQ-R, QSU,
MNWS and VAS data. Mood (VAS) and craving (QSU
and VAS) data will be analyzed in two time-phase analyses
using ANOVA. We will first assess general (i.e., not cue-
related)cravingacross drug treatment using baseline data
from sessions one and two in a two (pre- and post-drug
treatment) × two (varenicline and placebo) mixed-model
ANOVA. We will also examine craving and mood change
across CBM in a two (pre- and post-CBM) × two (vareni-
cline and placebo) × three (attend, avoid, and control)
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and drug is a between-subjects factor.
Discussion
This study will investigate the neural effects of smoking-
related CBM in daily smokers. We will also examine
whether one-week’s treatment of the licensed smoking
cessation pharmacotherapy varenicline alters neural re-
sponse to smoking-related cues. Within this data set, we
will be able to explore whether there is any pattern sug-
gesting an interactive effect of CBM and varenicline.
These are novel questions in this field and will inform
future research with a better understanding of the mech-
anisms that may underlie CBM. As CBM is a treatment
which can be delivered remotely via computers, tablets,
or smartphones it could therefore provide a cost-
effective intervention that could be used, in conjunction
with more traditional pharmacotherapies and behavioral
support, to help promote long-term smoking cessation
and reduce relapse rates.
This study will recruit daily smokers who are not cur-
rently trying to quit smoking. Therefore this is an
analogue sample and participants have not been re-
cruited on the basis of seeking cessation support. The
primary reason for this is due to the proposed mechan-
ism by which varenicline impacts on cue reactivity. Al-
though this mechanism has not been unequivocally
established, it is suggested that smoking cues lose incen-
tive salience during varenicline treatment due to its at-
tenuation of smoking reinforcement. That is, individuals
experience reduced reward from smoking and this is as-
sociated with drug-related cues. For this process to
occur however, individuals need to smoke to experience
the attenuated smoking reinforcement. For the purposes
of this study, it was not considered ethical to enroll
smokers motivated to quit as their participation may
maintain smoking and delay a quit attempt. Recruitment
of non-quitting smokers also avoids interference of other
smoking-related treatments such as nicotine replace-
ment therapy or behavioral support. This study will pro-
vide a basis to examine treatment effects of varenicline
and CBM on cognitive bias and cue-related responses
that can inform future research in quitting populations.
Trial status
As of March 2014, 55 participants have been enrolled
onto the study. The first participant was enrolled in
November 2012 and completion of data collection is
projected for June 2014.
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